I think the timeline for approval is a little later than most investors were anticipating. I believe we will get updates at certain milestones which will hopefully show results are positive. I think the reason for delay from the completion of trials and FDA approval is it probably takes FDA a decent amount of time to review all the data and make a decision. One thing is for sure, nothing in the drug business happens quickly.
I still see a lot of growth opportunity this year with the stock. We are undervalued for a phase 3 company. And I think we'll get more partnerships with companies announced hopefully. I plan on buying more if this doesnt gap up too much when it opens.
News 
Market Data 
Discover 
